SunBio, Inc.

As of June 30, 2026, SunBio, Inc. carries a market capitalization of 77.98B, placing it among publicly traded companies globally. Its enterprise value stands at 103.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SunBio, Inc. has 12.16M shares outstanding.

As of June 30, 2026, SunBio, Inc. trades at a trailing price-to-earnings ratio of 18.07. The price-to-sales ratio is 6.26, and the price-to-book ratio stands at 2.60.

As of June 30, 2026, SunBio, Inc. trades at an EV/EBITDA multiple of 15.99 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.13 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. SunBio, Inc. trades at an EV/FCF ratio of 43.76, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 103.41B versus a market cap of 77.98B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SunBio, Inc. maintains a current ratio of 0.46, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 97.81, indicating elevated leverage, while an interest coverage ratio of 5.57 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SunBio, Inc. posted a return on equity (ROE) of 15.55, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.54 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.02, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.59, useful for judging operating efficiency across full business cycles. The company generates approximately 452.81M in revenue per employee across its workforce of 27.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.98 indicates how many times SunBio, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SunBio, Inc. recorded 208.21M in income tax expense. That works out to an effective tax rate of 4.60, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.52B, leaving 4.31B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, SunBio, Inc.'s stock has declined approximately 2.80% over the past 52 weeks. The 50-day moving average sits at 5,924.80, while the 200-day moving average is 5,993.40.

Over the twelve months ended June 30, 2026, SunBio, Inc. generated 12.45B in revenue and converted that into 4.31B in net income, yielding earnings per share of 354.79. EBITDA reached 6.47B, while operating income came in at 4.47B.

As of June 30, 2026, SunBio, Inc. holds 3.87B in cash and equivalents against 29.31B in total debt, resulting in a net debt position of 25.44B. Total book value stands at 29.96B, with working capital of -18.54B providing operational flexibility.

SunBio, Inc. produced 3.07B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.82B in capital expenditures, free cash flow totaled 1.25B - equivalent to 103.19 per share.

Over the twelve months ended June 30, 2026, SunBio, Inc. posted a gross margin of 60.52, reflecting its pricing power and cost economics. The operating margin of 35.90 and net profit margin of 34.64 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.61, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.23, meaning SunBio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

SunBio, Inc.'s most recent stock split took place on January 7, 2021 with a 2:3 split ratio.

As of June 30, 2026, SunBio, Inc. has an Altman Z-Score of 1.64, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.